cidara
therapeutics
present
new
clinical
preclinical
data
rezafungin
influenza
avcs
idweek
san
diego
globe
newswire
cidara
therapeutics
nasdaq
cdtx
biotechnology
company
developing
therapeutics
designed
transform
standard
care
patients
facing
serious
fungal
viral
infections
today
announced
present
two
oral
abstracts
seven
posters
idweek
joint
annual
meeting
infectious
diseases
society
america
idsa
society
healthcare
epidemiology
america
shea
hiv
medical
association
hivma
pediatric
infectious
diseases
society
pids
society
infectious
diseases
pharmacists
sidp
takes
place
virtually
cidara
detail
new
findings
related
rezafungin
novel
echinocandin
phase
trials
treatment
prevention
serious
fungal
infections
five
poster
presentations
details
follows
title
phase
strive
clinical
trial
rezafungin
treatment
candidemia
invasive
candidiasis
demonstrates
consistent
trough
concentrations
across
diverse
patient
populations
poster
id
presenter
shawn
flanagan
cidara
date
wednesday
session
medical
mycology
title
outcomes
baseline
pathogens
susceptibility
strive
phase
trial
rezafungin
treatment
candidemia
invasive
candidiasis
compared
caspofungin
poster
id
presenter
george
thompson
iii
university
california
davis
date
wednesday
session
novel
agents
title
outcomes
body
mass
index
bmi
strive
phase
trial
rezafungin
treatment
candidemia
invasive
candidiasis
compared
caspofungin
poster
id
presenter
jose
vazquez
medical
college
georgia
augusta
university
date
wednesday
session
clinical
trials
title
pharmacokinetics
excretion
mass
balance
following
intravenous
iv
administration
healthy
adults
poster
id
presenter
voon
ong
cidara
date
wednesday
session
novel
agents
title
pharmacoepidemiologic
evaluation
echinocandin
use
poster
id
presenter
jinhee
jo
university
houston
date
wednesday
session
poster
session
antimicrobial
stewardship
outcomes
assessment
clinical
economic
cidara
detail
new
findings
cloudbreak
antiviral
platform
specifically
prevention
treatment
influenza
two
oral
two
poster
presentations
development
candidate
details
follows
title
efficacy
novel
antiviral
seasonal
influenza
lethal
mouse
infection
models
oral
abstract
id
presenter
james
levin
cidara
format
demand
session
novel
vaccines
antibodies
title
novel
antiviral
demonstrates
potent
viral
burden
reduction
influenza
mouse
ferret
models
oral
abstract
id
presenter
simon
d√∂hrmann
cidara
format
demand
session
novel
vaccines
antibodies
title
new
generation
antiviral
conjugate
avc
stable
safe
single
poster
id
presenter
voon
ong
cidara
date
wednesday
session
novel
agents
title
evaluation
novel
antiviral
avc
vitro
activity
vivo
efficacy
scid
lethal
mouse
models
poster
id
presenter
james
levin
cidara
date
wednesday
session
novel
agents
copies
abstracts
made
available
publications
section
cidara
website
additional
details
found
idweek
interactive
program
planner
rezafungin
rezafungin
novel
echinocandin
developed
treatment
prevention
serious
fungal
infections
candidemia
invasive
candidiasis
structure
properties
rezafungin
specifically
designed
improve
upon
clinically
validated
mechanism
intended
enhance
efficacy
safety
potential
patients
cidara
currently
conducting
phase
clinical
trial
rezafungin
treatment
candidemia
invasive
candidiasis
restore
trial
second
phase
clinical
trial
rezafungin
prevention
invasive
fungal
disease
patients
undergoing
allogeneic
blood
marrow
transplantation
respect
trial
cloudbreak
avcs
cidara
developing
new
generation
immunotherapeutic
antivirals
cloudbreak
antiviral
platform
couple
potent
antivirals
human
antibody
fragment
antiviral
conjugates
avcs
directly
inhibit
viral
proliferation
simultaneously
engaging
immune
system
avcs
initially
studied
prevention
treatment
seasonal
pandemic
influenza
potential
deliver
universal
protection
entire
flu
season
single
dose
cidara
also
advancing
preclinical
discovery
avc
programs
target
viruses
rsv
hiv
cov
including
cidara
therapeutics
cidara
developing
therapeutics
designed
transform
standard
care
patients
facing
serious
fungal
viral
infections
company
portfolio
comprised
lead
antifungal
candidate
rezafungin
addition
antiviral
conjugates
avcs
prevention
treatment
influenza
viral
diseases
cidara
proprietary
antiviral
platform
cidara
headquartered
san
diego
california
information
please
visit
statements
release
contains
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
statements
describe
future
expectations
plans
results
strategies
generally
preceded
words
anticipates
expect
may
plan
statements
release
include
limited
statements
related
rezafungin
potential
treatment
ability
prevent
severe
fungal
infections
statements
related
avcs
potential
directly
inhibit
viral
proliferation
simultaneously
engaging
immune
system
ability
influenza
avc
deliver
universal
protection
entire
flu
season
single
dose
statements
subject
multitude
risks
uncertainties
could
cause
future
circumstances
events
results
differ
materially
projected
statements
unanticipated
delays
negative
results
cidara
clinical
trials
obstacles
development
rezafungin
risks
identified
caption
risk
factors
cidara
recent
quarterly
report
form
filings
subsequently
made
securities
exchange
commission
statements
contained
press
release
speak
date
made
based
management
assumptions
estimates
date
cidara
undertake
obligation
publicly
update
statements
whether
result
receipt
new
information
occurrence
future
events
otherwise
investor
contact
brian
ritchie
lifesci
advisors
britchie
media
contact
karen
shea
lifesci
communications
koshea
